Akari Therapeutics Data On PH1 ADC Payload Shows Ability To Induce Both Cancer Cell Cytotoxicity, Activation Of Anti-tumor Immunity With Multiple Mechanisms

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the presentation of immune mechanism-of-action data for its novel ADC payload, PH1.

The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms.

Treatment with a Trastuzumab-PH1 ADC monotherapy drove macrophages to polarize into an anti-tumor/inflammatory state and caused expansion of B cell clones and subsequent IgM antibodies

When combined with anti-PD1 therapy, additional effects included expansion of Gamma-Delta T cell clones demonstrating that the combined regimen drives innate, adaptive, and humoral immunity against the tumor

In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% v 42%, p<0.05)

These data, which demonstrate the true synergy of an ADC using the spliceosome targeting PH1 payload with a checkpoint inhibitor, have the potential to expand the immuno-oncology therapeutic class that is currently at ~$50 Billion/year